Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1990 Sep;49(9):690–693. doi: 10.1136/ard.49.9.690

Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.

N J Struyf 1, H W Snoeck 1, C H Bridts 1, L S De Clerck 1, W J Stevens 1
PMCID: PMC1004205  PMID: 1700674

Abstract

Natural killer (NK) cell activity and its stimulation by interferons (IFNs) and interleukin-2 (IL-2) are diminished in Sjögren's syndrome and systemic lupus erythematosus (SLE). Serum samples of these patients often contain circulating immune complexes, which may influence NK cell activity. Sixteen patients with Sjögren's syndrome (14/16 immune complex positive), 14 with SLE (9/14 immune complex positive), and 11 controls (immune complex negative) were studied. Mononuclear cells collected from a Percoll gradient were preincubated with recombinant IFN-alpha (rIFN-alpha) (100 U/ml), rIFN-gamma (1000 U/ml), rIL-2 (100 U/ml), or without cytokine. Natural killer cell activity was determined by incubating the mononuclear cells with carboxyfluorescein labelled K562 cells, and the percentage decrease of fluorescence was measured on an FACS Analyzer. In patients with Sjögren's syndrome and SLE NK cell activity and the numbers of cells expressing the NK cell associated antigens CD16 and Leu7 were diminished compared with the controls. Interleukin-2 stimulated NK cell activity significantly in comparison with the non-stimulated value in all studied groups, whereas IFN-gamma only stimulated NK cell activity in both patient groups and IFN-alpha only in patients with Sjögren's syndrome. There was no correlation between NK cell activity, with or without stimulation, and the immune complex concentrations. It is concluded that NK cell activity is decreased in Sjögren's syndrome and SLE and that it may be partially restored by IL-2 and IFN-gamma in both diseases, and by IFN-alpha in Sjögren's syndrome. The decrease of NK cell activity did not correlate with immune complex concentrations; on the other hand, decreased numbers of NK cells (CD16+ or Leu7+) and of cytokine concentrations might be important in the impaired NK cell activity in both diseases.

Full text

PDF
690

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. De Clerck L. S., Gigase P. L., Bridts C. H., Stevens W. J. Role of IgM-rheumatoid factor interference in the determination of total serum IgE and IgE-containing circulating immune complexes. Clin Exp Immunol. 1988 Apr;72(1):32–36. [PMC free article] [PubMed] [Google Scholar]
  3. Domzig W., Stadler B. M., Herberman R. B. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol. 1983 Apr;130(4):1970–1973. [PubMed] [Google Scholar]
  4. Egan M. L., Mendelsohn S. L., Abo T., Balch C. M. Natural killer cells in systemic lupus erythematosus. Abnormal numbers and functional immaturity of HNK-1+ cells. Arthritis Rheum. 1983 May;26(5):623–629. doi: 10.1002/art.1780260508. [DOI] [PubMed] [Google Scholar]
  5. Fitzharris P., Alcocer J., Stephens H. A., Knight R. A., Snaith M. L. Insensitivity to interferon of NK cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 1982 Jan;47(1):110–118. [PMC free article] [PubMed] [Google Scholar]
  6. Gonzalez-Amaro R., Alcocer-Varela J., Alarcón-Segovia D. Natural killer cell activity in the systemic connective tissue diseases. J Rheumatol. 1988 Aug;15(8):1223–1228. [PubMed] [Google Scholar]
  7. Goto M., Tanimoto K., Chihara T., Horiuchi Y. Natural cell-mediated cytotoxicity in Sjögren's syndrome and rheumatoid arthritis. Arthritis Rheum. 1981 Nov;24(11):1377–1382. doi: 10.1002/art.1780241107. [DOI] [PubMed] [Google Scholar]
  8. Goto M., Tanimoto K., Horiuchi Y. Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum. 1980 Nov;23(11):1274–1281. doi: 10.1002/art.1780231108. [DOI] [PubMed] [Google Scholar]
  9. Ichikawa Y., Yoshida M., Takaya M., Uchiyama M., Shimizu H., Arimori S. Circulating natural killer cells in Sjögren's syndrome. Arthritis Rheum. 1985 Feb;28(2):182–187. doi: 10.1002/art.1780280213. [DOI] [PubMed] [Google Scholar]
  10. Ishida H., Kumagai S., Umehara H., Sano H., Tagaya Y., Yodoi J., Imura H. Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1987 Aug 15;139(4):1070–1074. [PubMed] [Google Scholar]
  11. Karsh J., Dorval G., Osterland C. K. Natural cytotoxicity in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1981 Jun;19(3):437–446. doi: 10.1016/0090-1229(81)90086-6. [DOI] [PubMed] [Google Scholar]
  12. Kim T., Kanayama Y., Negoro N., Okamura M., Takeda T., Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987 Dec;70(3):562–569. [PMC free article] [PubMed] [Google Scholar]
  13. Lakhanpal S., Handwerger B. S. Interleukin 2 receptors and responsiveness to recombinant human interleukin 2 in patients with systemic lupus erythematosus. Mayo Clin Proc. 1987 Jan;62(1):3–7. doi: 10.1016/s0025-6196(12)61519-5. [DOI] [PubMed] [Google Scholar]
  14. Linker-Israeli M., Casteel N. Partial purification and characterization of systemic lupus erythematosus derived factors that suppress production of interleukin-2. J Rheumatol. 1988 Jun;15(6):952–958. [PubMed] [Google Scholar]
  15. Lozzio C. B., Lozzio B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975 Mar;45(3):321–334. [PubMed] [Google Scholar]
  16. McGinnes K., Chapman G., Marks R., Penny R. A fluorescence NK assay using flow cytometry. J Immunol Methods. 1986 Jan 22;86(1):7–15. doi: 10.1016/0022-1759(86)90258-9. [DOI] [PubMed] [Google Scholar]
  17. Minato N., Takeda A., Kano S., Takaku F. Studies of the function of natural killer-interferon system in patients with Sjögren syndrome. J Clin Invest. 1982 Mar;69(3):581–588. doi: 10.1172/JCI110484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  19. Neighbour P. A., Grayzel A. I. Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol. 1981 Sep;45(3):576–582. [PMC free article] [PubMed] [Google Scholar]
  20. Neighbour P. A., Grayzel A. I., Miller A. E. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol. 1982 Jul;49(1):11–21. [PMC free article] [PubMed] [Google Scholar]
  21. Pedersen B. K., Oxholm P., Manthorpe R., Andersen V. Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome. Clin Exp Immunol. 1986 Jan;63(1):1–7. [PMC free article] [PubMed] [Google Scholar]
  22. Sibbitt W. L., Froelich C. J., Bankhurst A. D. Natural cytotoxicity in systemic lupus erythematosus: mechanisms of suppression by inhibitory serum factors. Clin Exp Immunol. 1983 Aug;53(2):363–370. [PMC free article] [PubMed] [Google Scholar]
  23. Sibbitt W. L., Jr, Likar L., Spellman C. W., Bankhurst A. D. Impaired natural killer cell function in systemic lupus erythematosus. Relationship to interleukin-2 production. Arthritis Rheum. 1983 Nov;26(11):1316–1320. doi: 10.1002/art.1780261103. [DOI] [PubMed] [Google Scholar]
  24. Sibbitt W. L., Jr, Mathews P. M., Bankhurst A. D. Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest. 1983 May;71(5):1230–1239. doi: 10.1172/JCI110872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stevens W. J., Bridts C. A method for rapid determination of IgG containing circulating immune complexes using polyethyleneglycol and radioactively labeled protein A. Immunol Lett. 1981 Apr;3(1):1–4. doi: 10.1016/0165-2478(81)90086-9. [DOI] [PubMed] [Google Scholar]
  26. Strannegård O., Hermodsson S., Westberg G. Interferon and natural killer cells in systemic lupus erythematosus. Clin Exp Immunol. 1982 Nov;50(2):246–252. [PMC free article] [PubMed] [Google Scholar]
  27. Takeda A., Minato N., Kano S. Selective impairment of alpha-interferon-mediated natural killer augmentation in Sjögren's syndrome: differential effects of alpha-interferon, gamma-interferon, and interleukin 2 on cytolytic activity. Clin Exp Immunol. 1987 Nov;70(2):354–363. [PMC free article] [PubMed] [Google Scholar]
  28. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  29. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med. 1978 May 1;147(5):1314–1333. doi: 10.1084/jem.147.5.1314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tsokos G. C., Rook A. H., Djeu J. Y., Balow J. E. Natural killer cells and interferon responses in patients with systemic lupus erythematosus. Clin Exp Immunol. 1982 Nov;50(2):239–245. [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES